Genetic testing can predict bladder cancer diagnosis years in advance

Published Date: 17 Mar 2023

Bladder cancer is not a rare disease. It is one of the 10 most common cancers in the UK and the 5th most common cancer in the European Union.

Read Full News

Latest News

Vasectomy Reversal More Cost-Effective Than IVF

Most couples younger than 40 years can achieve pregnancy within typical $30,000-$40,000 employer fertility benefits with reversal, new research indicates.

US Judge Rejects Bayer Bid to Block Johnson & Johnson Prostate Cancer Drug Claims

A U.S. judge has rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that ⁠its multibillion-dollar drug cuts the risk of...

This Test Could Predict Incontinence Risk After HoLEP

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

Smartphone App Helps Delay Ejaculation

The app improves sexual control and doubles ejaculation latency time in a randomized trial.

US FDA Approves Lantheus' New Prostate Cancer Imaging Formulation

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate ⁠cancer imaging agent, aimed at improving scanning access through...

Will a Smart Toilet Turn the Home Into a Diagnostic Center?

Smart toilets show promise for passive monitoring of stool and urine to detect potential health issues, but challenges remain.

Todays Updates

NP-Led Outreach Ups Cancer Screening in Rural Women Veterans

A nurse practitioner-led outreach program improves the rates of breast and cervical cancer screening among women veterans in rural areas, a retrospective study shows.

Less Mental Decline With Darolutamide vs Enzalutamide in PC

Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.

Todays Updates

NP-Led Outreach Ups Cancer Screening in Rural Women Veterans

A nurse practitioner-led outreach program improves the rates of breast and cervical cancer screening among women veterans in rural areas, a retrospective study shows.

Less Mental Decline With Darolutamide vs Enzalutamide in PC

Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.

Latest News

Most couples younger than 40 years can achieve pregnancy within typical $30,000-$40,000 employer fertility benefits with reversal, new research indicates.

A U.S. judge has rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that ⁠its multibillion-dollar drug cuts the risk of...

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

The app improves sexual control and doubles ejaculation latency time in a randomized trial.

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate ⁠cancer imaging agent, aimed at improving scanning access through...

Smart toilets show promise for passive monitoring of stool and urine to detect potential health issues, but challenges remain.

News All Time

During the Accountable Care Meeting, CMS Officials were pressed on the topic of scanner fraud.

"We would appreciate it if you could give the matter more immediate attention," one ACO member said.

Nivolumab Plus Chemotherapy in First Line Approved for Bladder Cancer.

Combination decreased death risk by 22%.

King Charles III's Operation; COVID-19 Timeline Under Question; FDA Approvals Reach Record High.

The staff of MedPage Today has compiled health news and commentary from around the web.

Noninvasive Treatment Effective in Bladder Cancer That Is Not Muscle-Invasive.

An investigational intrusive solution produced a 79% complete response rate.

For Prostate Cancer at Intermediate Risk, SBRT Is Not Less Effective Than Conventional RT.

Similar results are obtained from treatment lasting one to two weeks as compared to therapy lasting up to seven and a half weeks.

The new first-line standard for advanced bladder cancer was produced by a landmark trial.

When compared to chemotherapy, enfortumab vedotin-pembrolizumab doubles OS and PFS.

Should Patients With Advanced Prostate Cancer Get Off the Active Surveillance Train?

Clearly defined rules are needed.

Even in those with HIV, a single dose of antibiotics was able to cure early syphilis.

In a randomized trial, one dosage showed no worse results than a triple-dose regimen.

Removing Cancer Survivors From Oncologic Treatment.

A new approach to care is required.

Cabazitaxel Lower-Dose Schedule Is Viable for Elderly Patients With mCRPC.

Neutropenia of grade three or above, with a twelve-fold reduction in neutropenic consequences.

AR-Pathway Inhibitor Switch for mCRPC is Superseded by Radionuclide Therapy.

With 177Lu-PSMA-617, the time to radiographic progression was doubled.

An RCT Supports HIF-2a Inhibition in Advanced RCC.

Belzutifan outperforms everolimus in the event of immunotherapy-TKI failure.

Finding New Routes to Improve Renal Cell Carcinoma Outcomes.

It is necessary to intervene at several stages of the cancer immunity cycle in order to build on recent successes.

CAR T-Cell Therapy for Renal Cell Carcinoma: "We're Not There Yet".

Possibility of standard of care following current therapies, but significant barriers still need to be overcome.

In severe cases of renal cell carcinoma, tyrosine kinase inhibitor activity is present.

Reactions to the "special medication" zanzalintinib in patients exposed and not exposed to cabozantinib.

Dietary inflammation is associated with the development of urologic cancers.

In health research, the relationship between dietary habits and cancer risks is still a major focus. The has been the subject of a recent meta-analysis.

Recommended News For You

Exercise may help breast cancer survivors manage weight

FDA-approved FGFR inhibitors show promise against rare and aggressive pediatric brain tumor

Sydney researchers identify new tools to improve cancer diagnosis and treatment.

'It's rare and it's scary.' Dark spot on your fingernail could mean cancer

Survivors of high-risk neuroblastoma face substantial late effects of modern therapies

Scientists identify dual protein targets to weaken pancreatic cancer defenses

Waiting for a Sharp Increase in Prostate Cancer Cases.

Recommended Articles For You

The Danger of Methemoglobinemia and How to Prevent It  

Beyond the Organs: Navigating the Era of Tissue-Agnostic Therapies in Modern Cancer Management 

The Capmist DM: A Revolutionary Way to Combat Dry Mouth 

Everything You Need to Know About the Latest Hyponatremia Algorithm  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Two medications might work better for breast cancers that are resistant to one.

2.

Can Oncotype Predict Recurrence Risk in Older BC Patients?

3.

Surgeons are at higher risk of cancer, study suggests

4.

Kidney cancer: Understanding what a renal cell carcinoma diagnosis means

5.

Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.

1.

Demystifying Lymphocytes: Everything You Need to Know 

2.

The Role of Alanine Aminotransferase in Liver Health and Disease 

3.

The Danger of Rectus Sheath Hematoma: A Hidden Risk of Abdominal Surgery

4.

Preventing Heparin Induced Thrombocytopenia: Tips for Successful Anticoagulation Therapy 

5.

Survivin as a Key Regulator in Gynecological Cancers: Therapeutic and Prognostic Implications

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.

2.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation

3.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III

4.

Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases

5.

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot